EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Marker Therapeutics's Enterprise Value is $19.05 Mil.
Marker Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-16.55 Mil. Therefore, Marker Therapeutics's EV-to-FCF for today is -1.15.
The historical rank and industry rank for Marker Therapeutics's EV-to-FCF or its related term are showing as below:
MRKR'
s EV-to-FCF Range Over the Past 10 Years
Min: -21.1 Med: -2.52 Max: 1.38
Current: -1.15
During the past 13 years, the highest EV-to-FCF of Marker Therapeutics was 1.38. The lowest was -21.10. And the median was -2.52.
MRKR's EV-to-FCF is ranked worse than 100% of 381
companies
in the Biotechnology industry
Industry Median: 7.56
vs MRKR: -1.15
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Marker Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Marker Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Marker Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marker Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Marker Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Marker Therapeutics's EV-to-FCF falls into.
Marker Therapeutics's current Enterprise Value is $19.05 Mil.
Marker Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.55 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Marker Therapeutics's PE Ratio for today is calculated as:
Marker Therapeutics's share price for today is $4.10.
Marker Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.940.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Marker Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Marker Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Marker Therapeutics (Marker Therapeutics) Business Description
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MRKR has been successfully added to your 